BioMarin has told California it will lay off 117 employees at its Novato plant, effective December 4, Fierce Pharma reports from the WARN filing. A local newspaper’s headline puts the figure at 119; we use the 117 in the Fierce report. The company’s stated reason is consolidation. AI and automation appear nowhere in what has been published, so this goes in our file for cuts where AI is not the cause, and it stays there.
What was filed
Novato makes active pharmaceutical ingredient for several of BioMarin’s rare-disease products, including Aldurazyme, Naglazyme, Palynziq and Voxzogo. A spokesperson said the reduction is part of an ongoing evaluation of the company’s global footprint, and that BioMarin is consolidating into 「a smaller, more focused site」. The company also promised support and severance for affected employees.
The cut lands about two weeks after BioMarin halted development of Voxzogo for Noonan syndrome in children. The company says the layoffs are unrelated to that decision. We have no source that says otherwise, so we take the statement as given and note only that the two news items sit close together.
It is not BioMarin’s first cut this year. In May it laid off 58 people at the former Amicus Therapeutics headquarters in Princeton, New Jersey, shortly after closing its $4.8B acquisition of Amicus. Adding the two gives 175 positions across two filings that we can document. The company’s total headcount is not in the sources we could open, so we cannot give a percentage, and we will not guess one.
Why a 117 gets a write-up
The threshold we use for a no-AI cut is 100 roles at a widely watched employer, and the pharma sector has been giving us a steady supply. Bristol Myers Squibb filed 265 more on September 22, taking its New Jersey total this year to 718, also without naming AI. Greggs proposed 740 on September 30, the same day the BioMarin cut was reported, and Bosch’s Nuremberg plan is 900 of 1,800. Against that cohort, 117 is small in headcount.
What sets BioMarin apart is the shape. Bristol and Greggs each cut within a larger footprint. BioMarin is pulling manufacturing out of a site to concentrate it elsewhere, which is a different kind of cut from white-collar attrition. It is also a contrast with Novo Nordisk’s September 21 disclosure, where the headcount fall of about 13,000 arrived in the same deck as a claim that AI made clinical study reports ten times faster. In that case a company drew its own line from AI to headcount. BioMarin draws none.
What this means for a specific career
The roles at risk are physical ones: API manufacturing operators, process technicians, quality control analysts and chemists, maintenance and engineering staff, and the warehouse and site-support people attached to a plant. These are not the jobs that AI-exposure tools usually flag, and a model-readiness plan does not protect any of them.
For an affected worker, the useful facts are practical. December 4 is the effective date, so the notice period is already running. Bay Area biologics and cell-therapy manufacturers hire for the same skills, and process and QC experience travels across them. For a reader elsewhere in pharma manufacturing, the pattern to watch is the one named in BioMarin’s own statement: a company that owns more than one site and says it is evaluating its footprint is signalling that one site may not survive the review.
What to watch
Whether BioMarin names further site actions in its next quarterly results, which would show if Novato is the first step of a larger consolidation. Whether the company says anything about where the Novato output moves, since a transfer to a more automated site would turn this into a different article. And the next California WARN batch for other Marin County biotech sites. Until a source says automation is involved, this is a footprint cut, and we will keep it labeled that way.
